INCHEON Korea&8211;BUSINESS WIRE&8211;Samsung Bioepis Co. Ltd. today announced that the US Food and Drug Administration FDA has approved HADLIMA adalimumabbwwd a biosimilar referencing HUMIRAÂ iÂadalimumab for the treatment of rheumatoid arthritis ...
↧